Mabpharm Limited (HKG:2181)
0.4250
-0.0050 (-1.16%)
Nov 3, 2026, 4:08 PM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.75 billion as of November 2, 2026. It is the 19,786th most valuable company in the world and the 885th biggest in Hong Kong. Its market cap has decreased by 18.27% in one year.
Market Cap
1.75B
Enterprise Value
2.00B
Revenue
888.77M
Global Rank
Country Rank
#885 Hong Kong
PE Ratio
19.08
ChartMarket Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.75B, a decrease of -64.88%. That is a compound annual growth rate of -13.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 3, 2026 | 1.75B | -15.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 2.47B |
| Laekna | 2.43B |
| HJ Science | 2.28B |
| HighTide Therapeutics | 2.09B |
| Shandong Boan Biotechnology | 1.99B |
| Antengene Corporation | 1.95B |
| AIM Vaccine | 1.88B |
| Clover Biopharmaceuticals | 1.66B |